The preterm infant's immune response to an acellular pertussis-Hib and meningitis C conjugate vaccine given together

100 infants born at 31 weeks gestation or less will be immunised with a combined three component acellular pertussis-HIB vaccine at the same time as a meningitis C conjugate vaccine at 2, 3 and 4 months of age.

Scientific version
  • Researchers:
    Dr Elizabeth Miller, Dr Martin Slack, Dr Richard Thwaites
  • Start Date:
    01 June 2000
  • Category:
    Prevention
  • Location:
    Portsmouth Hospitals NHS Trust, Portsmouth, UK
The preterm infant's immune response to an acellular pertussis-Hib and meningitis C conjugate vaccine given together

100 infants born at 31 weeks gestation or less will be immunised with a combined three component acellular pertussis-HIB vaccine at the same time as a meningitis C conjugate vaccine at 2, 3 and 4 months of age. They will be recruited from the neonatal units of the 5 participating hospitals: Portsmouth, Winchester, Southampton, Basingstoke, and Poole. Antibody titres to vaccine antigens will be determined just prior to the first immunisation and 4 weeks after the last.

Where immune response is inadequate to either Hib or men C a booster dose will be offered. Where this occurs, post booster sera will be assayed for antibodies to meningo C or Hib as appropriate, including measurement of antibody avidity to confirm induction of immunological memory.

All vaccine antibody levels will be analysed by laboratories participating in the National Vaccine Evaluation Consortium co-ordinated by the Public Health Laboratory Service, London.

Results will be analysed according to the infant's gestation, birth weight and use of dexamethasone at any time.

Results will be directly comparable to previous studies performed by the senior applicant in term infants for both Hib and men C.

meningitis & septicaemia can kill in hours!

People who are faced with meningitis and septicaemia have to act fast to help save a life.

Ask the Expert
Professor Chris Tang

Why are MRF continuing to fund MenB research?

Read more